BackgroundCheck.run
Search For

Brian P Bettencourt, 4596 Clark Ave, Dracut, MA 01826

Related to:
Melinda Bettencourt 42 Nicholas Bettencourt 42 Edelmirra Durden Melinda Greenwood 49 David Greenwood 63 Edelmira Durden 63 Brian Durden 62

Brian Bettencourt Phones & Addresses

96 Clark Ave, Dracut, MA 01826    978-8055957   

58 Crosby St, Lowell, MA 01852    978-4542061   

26 Ash St, Lowell, MA 01852   

130 Bypass 28, Derry, NH 03038   

Get Report
Control this profile

Mentions for Brian P Bettencourt

Brian Bettencourt resumes & CV records

Resumes

Brian Bettencourt Photo 35

Owner At B&B Creative Concrete

Position:
Owner at B&B Creative Concrete
Location:
Greater Boston Area
Industry:
Construction
Work:
B&B Creative Concrete
Owner
Brian Bettencourt Photo 36

Brian Bettencourt

Location:
United States
Brian Bettencourt Photo 37

Brian Bettencourt

Location:
United States
Brian Bettencourt Photo 38

Brian Bettencourt

Location:
United States
Brian Bettencourt Photo 39

Entrepreneur

Location:
Greater Boston Area
Industry:
Construction

Publications & IP owners

Us Patents

Compositions And Methods For Inhibiting Expression Of Cd274/Pd-L1 Gene

US Patent:
2011025, Oct 13, 2011
Filed:
Apr 6, 2011
Appl. No.:
13/081270
Inventors:
Antonin DeFougerolles - Cambridge MA, US
Tatiana Novobrantseva - Cambridge MA, US
Brian Bettencourt - Cambridge MA, US
Assignee:
ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
A61K 31/713
C12N 15/63
A61P 35/00
C12N 5/10
C07H 21/02
A61P 31/18
US Classification:
514 44 A, 536 245, 435325, 4353201
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.

Compositions And Methods For Inhibiting Expression Of Mylip/Idol Gene

US Patent:
2013012, May 16, 2013
Filed:
Jan 25, 2011
Appl. No.:
13/575040
Inventors:
Brian Bettencourt - Cambridge MA, US
Kevin Fitzgerald - Cambridge MA, US
Muthiah Manoharan - Cambridge MA, US
Assignee:
ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
A61K 48/00
C12N 15/113
US Classification:
514 44 A, 536 245
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Mylip/Idol gene, and methods of using such dsRNA compositions to inhibit expression of Mylip/Idol.

Compositions And Methods Directed To Treating Liver Fibrosis

US Patent:
2013015, Jun 20, 2013
Filed:
Jun 2, 2011
Appl. No.:
13/701551
Inventors:
Greg Hinkle - Cambridge MA, US
Victor Kotelianski - Cambridge MA, US
Brian Bettencourt - Cambridge MA, US
Alfica Sehgal - Cambridge MA, US
Tatiana Novobrantseva - Cambridge MA, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/02
US Classification:
514 44 A, 536 245, 435325, 435375, 4353201
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-β, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-β, and SMAD2/3.

Compositions And Methods For Inhibiting Expression Of The Alas1 Gene

US Patent:
2013028, Oct 24, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/835613
Inventors:
Brian Bettencourt - Cambridge MA, US
Kevin Fitzgerald - Brookline MA, US
William Querbes - Cambridge MA, US
Robert J. Desnick - New York NY, US
Makiko Yasuda - New York NY, US
International Classification:
C12N 15/113
US Classification:
514 44 A, 536 245, 435325, 435375, 4353201
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

Serpinc1 Irna Compositions And Methods Of Use Thereof

US Patent:
2013031, Nov 28, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/837129
Inventors:
Alfica Sehgal - Cambridge MA, US
Ivanka Toudjarska - Cambridge MA, US
Donald Foster - Cambridge MA, US
Stuart Milstein - Cambridge MA, US
Brian Bettencourt - Cambridge MA, US
Martin A. Maier - Cambridge MA, US
Klaus Charisse - Cambridge MA, US
Satyanarayana Kuchimanchi - Cambridge MA, US
International Classification:
C12N 15/113
US Classification:
514 44 A, 536 245, 435375, 4353201, 514 44 R
Abstract:
The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.

Cell-Based Bioprocessing

US Patent:
2014000, Jan 2, 2014
Filed:
Jul 6, 2010
Appl. No.:
13/380182
Inventors:
Anthony Rossomando - Cambridge MA, US
Muthiah Manoharan - Cambridge MA, US
Gregory Hinkle - Cambridge MA, US
Brian Bettencourt - Cambridge MA, US
Stuart Pollard - Cambridge MA, US
David Kocisko - Newton MA, US
Shannon Hogan - Cambridge MA, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07K 16/28
US Classification:
435 703
Abstract:
The invention provides compositions and methods for producing an immunogenic agent from a host cell. In various embodiments, the immunogenic agent is a polypeptide, an antigen, a virus particle, or a vaccine In one aspect, the invention provides for a method for producing an immunogenic agent from a host cell. The method generally comprises contacting the cell with a RNA effector molecule, a portion of which is complementary to a target gene, maintaining the cell in a large-scale bioreactor for a time sufficient to modulate expression of the target gene, wherein the modulation enhances production of the immunogenic agent from the cell, and isolating the immunogenic agent from the cell.

Compositions And Methods For Inhibiting Expression Of Klf-1 And Bcl11A Genes

US Patent:
2014001, Jan 16, 2014
Filed:
Dec 9, 2011
Appl. No.:
13/992669
Inventors:
Tatiana Novobrantseva - Cambridge MA, US
Brian Bettencourt - Cambridge MA, US
Stuart Milstein - Cambridge MA, US
Anna Borodovsky - Cambridge MA, US
Assignee:
ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
C12N 15/113
US Classification:
514 44 A, 536 245, 435366, 435375, 4353201, 435370
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the KLF1 gene and the BCL11A gene, and methods of using such dsRNA compositions to inhibit expression of KLF1 and BCL11 A, respectively.

Compositions And Methods For Increasing Erythropoietin (Epo) Production

US Patent:
2014002, Jan 23, 2014
Filed:
Dec 9, 2011
Appl. No.:
13/992334
Inventors:
Victor Kotelianski - Cambridge MA, US
William Querbes - Cambridge MA, US
Brian Bettencourt - Cambridge MA, US
Assignee:
DANA-FARBER CANCER INSTITUTE - Boston MA
ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
C12N 15/113
US Classification:
514 44 A, 536 245, 435325, 435375
Abstract:
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.

Possible Relatives

Cynthia M Bettencourt  David Bettencourt  A A Bettencourt  Daniel J Bettencourt  Darin J Bettencourt  Fernando M Bettencourt  Frank J Bettencourt  Brian J Stanczyk  Brian P Standish  Brian R Standley 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.